Literature DB >> 9931261

Nuclear magnetic resonance and molecular dynamics studies on the interactions of the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins.

T Terada1, Y Ito, M Shirouzu, M Tateno, K Hashimoto, T Kigawa, T Ebisuzaki, K Takio, T Shibata, S Yokoyama, B O Smith, E D Laue, J A Cooper.   

Abstract

The Ras protein and its homolog, Rap1A, have an identical "effector region" (residues 32-40) preceded by Asp30-Glu31 and Glu30-Lys31, respectively. In the complex of the "Ras-like" E30D/K31E mutant Rap1A with the Ras-binding domain (RBD), residues 51-131 of Raf-1, Glu31 in Rap1A forms a tight salt bridge with Lys84 in Raf-1. However, we have recently found that Raf-1 RBD binding of Ras is indeed reduced by the E31K mutation, but is not affected by the E31A mutation. Here, the "Rap1A-like" D30E/E31K mutant of Ras was prepared and shown to bind the Raf-1 RBD less strongly than wild-type Ras, but slightly more tightly than the E31K mutant. The backbone 1H, 13C, and 15N magnetic resonances of the Raf-1 RBD were assigned in complexes with the wild-type and D30E/E31K mutant Ras proteins in the guanosine 5'-O-(beta,gamma-imidotriphosphate)-bound form. The Lys84 residue in the Raf-1 RBD exhibited a large change in chemical shift upon binding wild-type Ras, suggesting that Lys84 interacts with wild-type Ras. The D30E/E31K mutant of Ras caused nearly the same perturbations in Raf-1 chemical shifts, including that of Lys84. We hypothesized that Glu31 in Ras may not be the major salt bridge partner of Lys84 in Raf-1. A molecular dynamics simulation of a model structure of the Raf-1 RBD.Ras.GTP complex suggested that Lys84 in Raf-1 might instead form a tight salt bridge with Asp33 in Ras. Consistent with this, the D33A mutation in Ras greatly reduced its Raf-I RBD binding activity. We conclude that the major salt bridge partner of Lys84 in Raf-1 may be Asp33 in Ras. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931261     DOI: 10.1006/jmbi.1998.2472

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

1.  Sequential NMR assignment of the RAS-binding domain of Byr2.

Authors:  F Huber; W Gronwald; S Wohlgemuth; C Herrmann; M Geyer; A Wittinghofer; H R Kalbitzer
Journal:  J Biomol NMR       Date:  2000-04       Impact factor: 2.835

2.  Overcoming the problems associated with poor spectra quality of the protein kinase Byr2 using residual dipolar couplings.

Authors:  W Gronwald; E Brunner; F Huber; M Wenzler; C Herrmann; H R Kalbitzer
Journal:  Protein Sci       Date:  2001-06       Impact factor: 6.725

3.  Dynamic properties of the Ras switch I region and its importance for binding to effectors.

Authors:  M Spoerner; C Herrmann; I R Vetter; H R Kalbitzer; A Wittinghofer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 4.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

5.  Combined chemical shift changes and amino acid specific chemical shift mapping of protein-protein interactions.

Authors:  Frank H Schumann; Hubert Riepl; Till Maurer; Wolfram Gronwald; Klaus-Peter Neidig; Hans Robert Kalbitzer
Journal:  J Biomol NMR       Date:  2007-10-23       Impact factor: 2.835

6.  A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.

Authors:  Guowei Yin; Samantha Kistler; Samuel D George; Nora Kuhlmann; Leslie Garvey; Minh Huynh; Rachel K Bagni; Michael Lammers; Channing J Der; Sharon L Campbell
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

7.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

Authors:  Sai Krishna Athuluri-Divakar; Rodrigo Vasquez-Del Carpio; Kaushik Dutta; Stacey J Baker; Stephen C Cosenza; Indranil Basu; Yogesh K Gupta; M V Ramana Reddy; Lynn Ueno; Jonathan R Hart; Peter K Vogt; David Mulholland; Chandan Guha; Aneel K Aggarwal; E Premkumar Reddy
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

8.  The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS.

Authors:  James M Aramini; Sergey M Vorobiev; Lynda M Tuberty; Haleema Janjua; Elliot T Campbell; Jayaraman Seetharaman; Min Su; Yuanpeng J Huang; Thomas B Acton; Rong Xiao; Liang Tong; Gaetano T Montelione
Journal:  Structure       Date:  2015-07-09       Impact factor: 5.006

9.  Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.

Authors:  Benjamin Stieglitz; Christine Bee; Daniel Schwarz; Ozkan Yildiz; Anna Moshnikova; Andrei Khokhlatchev; Christian Herrmann
Journal:  EMBO J       Date:  2008-07-03       Impact factor: 11.598

Review 10.  Raf kinases: function, regulation and role in human cancer.

Authors:  Deborah T Leicht; Vitaly Balan; Alexander Kaplun; Vinita Singh-Gupta; Ludmila Kaplun; Melissa Dobson; Guri Tzivion
Journal:  Biochim Biophys Acta       Date:  2007-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.